Group shot of M7824 team. M7824, an investigational bifunctional immunotherapeutic, was discovered in-house at Merck KGaA, Darmstadt, Germany, by a team of medical thought leaders and scientists. Pictured above are members of the M7824 research team located Billerica, Massachusetts, US.

Merck KGaA, Darmstadt, Germany and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers